✦ LIBER ✦

Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma

✍ Scribed by Roehnisch, Tim; Then, Cornelia; Nagel, Wolfgang; Blumenthal, Christina; Braciak, Todd; Donzeau, Mariel; Böhm, Thomas; Flaig, Michael; Bourquin, Carole; Oduncu, Fuat S

Book ID: 125401159
Publisher: BioMed Central
Year: 2014
Tongue: English
Weight: 459 KB
Volume: 12
Category: Article
ISSN: 1479-5876
DOI: 10.1186/1479-5876-12-119

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of amsacrine in patients

Phase II trial of amsacrine in patients with multiple myeloma

✍ Greipp, Philip R. ;Coleman, Morton ;Anderson, Keaven ;McIntyre, O. Ross 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Seventy-four previously treated patients with multiple myeloma were treated with Amsacrine (m-AMSA) 120 mg/m2 every 3 weeks. A good response was observed in two patients (3%), and improvement was seen in three patients (4%). Severe toxicity was observed in 33% of patients who received three or more

Phase I/II clinical trial of sequential

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides

✍ Antonio Curti; Patrizia Tosi; Patrizia Comoli; Carolina Terragna; Elisa Ferri; C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

P135 Vaccination of myeloma patients wit

P135 Vaccination of myeloma patients with monoclonal immunoglobulin loaded dendritic cells: preclinical and first clinical results of a phase I/II clinical trial

✍ D. Očadlíková; L. Zahradová; L. Kovářová; J. Smejkalová; L. Pour; P. Vidláková; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 52 KB

A Phase I–II trial of polyethylene glyco

A Phase I–II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma

✍ Neeraj R. Agrawal; Ronald M. Bukowski; Lisa A. Rybicki; Joanne Kurtzberg; Lewis 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND Multiple myeloma remains an incurable disease. New agents are needed to improve therapy for patients with this disease. Previous investigators evaluated in vitro sensitivity of myeloma cells to polyethylene glycol‐conjugated L‐asparaginase (PEG‐L‐asparaginase) using the h

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Interferon alfa-2b/melphalan/prednisone

Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I–II trial

✍ M. Robert Cooper; Alexander Fefer; John Thompson; Delvyn C. Case; Raymond Kempf; 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 419 KB

Interferon alfa-2b (Intron A; Schering Plough) has been shown to be active in advanced previously treated multiple myeloma (MM). Recent in vitro evidence has suggested synergy between cytotoxic agents and interferon alfa-2b. This phase I-II protocol was initiated to study interferon alfa-2b in combi